HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its ...
Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge, Massachusetts-based biotech will ...
BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.
BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...
BridgeBio Pharma, Inc. recently announced a US$550,000,000 fixed-rate senior subordinated unsecured notes offering under Rule 144A, while updating investors on advancing late-stage programs and ...
If the acquisition is not completed by December 19, 2026, or upon certain other events, BioMarin would be required to redeem the notes at 100% of the issue price plus accrued interest.
The Bio-Rad Laboratories Inc.-Bond has a maturity date of 3/15/2032 and offers a coupon of 3.7000%. The payment of the coupon will take place 2,0 times per biannual on the 15.09.. At the current price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results